Funded Biotechnology Startups in Stockholm
Stockholm's biotechnology funding landscape spans early-stage seed deals through large growth rounds, with the 17 most recent disclosed transactions coveri…
Stockholm's biotechnology funding landscape spans early-stage seed deals through large growth rounds, with the 17 most recent disclosed transactions covering December 2020 through August 2025. The largest single round belongs to Calliditas Therapeutics, which closed $102M in December 2023, followed by Gesynta Pharma's $27M Series B in January 2025. Round types skew heavily toward "Series Unknown" classifications, though identifiable structures include two Series A rounds — Pixelgen Technologies in October 2023 and Elypta in June 2022 — alongside three seed rounds and one grant.
Pixelgen Technologies stands out for appearing twice in the dataset: a $6M seed in December 2022 followed by a $7M Series A in October 2023, a compressed stage progression completed within ten months. Deal sizes range from a $470K grant to Oncopeptides up through the nine-figure Calliditas round, with most disclosed amounts falling between $1M and $27M.
Most recent rounds
17 shownRelated listings
Frequently asked
What are the largest recent funding rounds among Stockholm biotech companies?
Calliditas Therapeutics closed the largest disclosed round at $102M in December 2023. Gesynta Pharma raised $27M in a Series B in January 2025, and both Affibody and Elypta closed $21M rounds in December 2022 and June 2022 respectively.
Which companies have raised multiple rounds in this dataset?
Pixelgen Technologies is the only company appearing more than once — a $6M seed in December 2022 followed by a $7M Series A in October 2023, a back-to-back progression completed within ten months.
How active was Stockholm biotech funding in 2023 compared to surrounding years?
Five of the 17 rounds closed in 2023, the highest count for any single calendar year in the dataset. Transactions that year ranged from UTI-lizer's $670K seed in May to Calliditas Therapeutics' $102M round in December, with NEOGAP Therapeutics, Pixelgen Technologies, and Sigrid Therapeutics also raising within that year.
What funding stages are represented among these Stockholm biotech companies?
Eight of the 17 rounds carry a Series Unknown classification and two have no stage listed, making more than half the dataset opaque on structure. Of the labeled rounds, there are three seeds (UTI-lizer, Pixelgen Technologies, Elsa), two Series A rounds (Elypta, Pixelgen Technologies), one Series B (Gesynta Pharma), and one grant (Oncopeptides).
Are there any grant-funded biotechnology companies in Stockholm shown here?
Yes — Oncopeptides received a $470K grant in September 2022, the only grant-type round among the 17 listed transactions.
What is the most recent funding activity visible in Stockholm biotech?
SciBase closed a $2M round on August 1, 2025, the most recent transaction in the dataset. Gesynta Pharma's $27M Series B in January 2025 is the second most recent.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.